These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 11125289)

  • 21. Cancer immunotherapy.
    Schuster M; Nechansky A; Kircheis R
    Biotechnol J; 2006 Feb; 1(2):138-47. PubMed ID: 16892244
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effective tumor targeting: strategies for the delivery of Armed Antibodies.
    MacDonald GC; Glover N
    Curr Opin Drug Discov Devel; 2005 Mar; 8(2):177-83. PubMed ID: 15782542
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Future directions of laser phototherapy for diagnosis and treatment of malignancies: fantasy, fallacy, or reality?
    Castro DJ; Saxton RE; Lufkin RB; Haugland RP; Zwarun AA; Fetterman HR; Soudant J; Castro DJ; Ward PH; Kangarloo H
    Laryngoscope; 1991 Jul; 101(7 Pt 2 Suppl 55):1-10. PubMed ID: 2062168
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Immunotherapy for cancer--modern immunologic strategies in oncology].
    Halama N; Zoernig I; Jäger D
    Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
    Kudo-Saito C; Schlom J; Camphausen K; Coleman CN; Hodge JW
    Clin Cancer Res; 2005 Jun; 11(12):4533-44. PubMed ID: 15958639
    [TBL] [Abstract][Full Text] [Related]  

  • 26. B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
    Kim S; Fridlender ZG; Dunn R; Kehry MR; Kapoor V; Blouin A; Kaiser LR; Albelda SM
    J Immunother; 2008 Jun; 31(5):446-57. PubMed ID: 18463540
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effective immunoconjugate therapy in cancer models targeting a serine protease of tumor fibroblasts.
    Ostermann E; Garin-Chesa P; Heider KH; Kalat M; Lamche H; Puri C; Kerjaschki D; Rettig WJ; Adolf GR
    Clin Cancer Res; 2008 Jul; 14(14):4584-92. PubMed ID: 18628473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In vivo diagnosis and therapy of human tumors with monoclonal antibodies. Part I. Proceedings of a symposium. Naples, Italy, 16-19 March 1988.
    Int J Rad Appl Instrum B; 1989; 16(2):103-185. PubMed ID: 2715003
    [No Abstract]   [Full Text] [Related]  

  • 29. Improved tumor targeting by combined use of two antitenascin antibodies.
    Petronzelli F; Pelliccia A; Anastasi AM; D'Alessio V; Albertoni C; Rosi A; Leoni B; De Angelis C; Paganelli G; Palombo G; Dani M; Carminati P; De Santis R
    Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7137s-7145s. PubMed ID: 16203813
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal antibodies in the treatment of lung cancer.
    Egri G; Takáts A
    Eur J Surg Oncol; 2006 May; 32(4):385-94. PubMed ID: 16504454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PAMAM structure-based multifunctional fluorescent conjugates for improved fluorescent labelling of biomacromolecules.
    Wängler C; Moldenhauer G; Saffrich R; Knapp EM; Beijer B; Schnölzer M; Wängler B; Eisenhut M; Haberkorn U; Mier W
    Chemistry; 2008; 14(27):8116-30. PubMed ID: 18752247
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 5T4 oncotrophoblast glycoprotein: janus molecule in life and a novel potential target against tumors.
    Zhao Y; Wang Y
    Cell Mol Immunol; 2007 Apr; 4(2):99-104. PubMed ID: 17484803
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Llama single-domain antibodies directed against nonconventional epitopes of tumor-associated carcinoembryonic antigen absent from nonspecific cross-reacting antigen.
    Behar G; Chames P; Teulon I; Cornillon A; Alshoukr F; Roquet F; Pugnière M; Teillaud JL; Gruaz-Guyon A; Pèlegrin A; Baty D
    FEBS J; 2009 Jul; 276(14):3881-93. PubMed ID: 19531051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Derlin-1 is overexpressed on the tumor cell surface and enables antibody-mediated tumor targeting therapy.
    Ran Y; Hu H; Hu D; Zhou Z; Sun Y; Yu L; Sun L; Pan J; Liu J; Liu T; Yang Z
    Clin Cancer Res; 2008 Oct; 14(20):6538-45. PubMed ID: 18927294
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antibody-guided radiation therapy of cancer.
    Koppe MJ; Postema EJ; Aarts F; Oyen WJ; Bleichrodt RP; Boerman OC
    Cancer Metastasis Rev; 2005 Dec; 24(4):539-67. PubMed ID: 16408161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Imaging the immune response to monitor tumor immunotherapy.
    Wang Q; Ornstein M; Kaufman HL
    Expert Rev Vaccines; 2009 Oct; 8(10):1427-37. PubMed ID: 19803763
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells.
    Hong F; Hansen RD; Yan J; Allendorf DJ; Baran JT; Ostroff GR; Ross GD
    Cancer Res; 2003 Dec; 63(24):9023-31. PubMed ID: 14695221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antibody-based therapeutics in oncology.
    Ross J; Gray K; Schenkein D; Greene B; Gray GS; Shulok J; Worland PJ; Celniker A; Rolfe M
    Expert Rev Anticancer Ther; 2003 Feb; 3(1):107-21. PubMed ID: 12597355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The evolution of antibodies into versatile tumor-targeting agents.
    Lin MZ; Teitell MA; Schiller GJ
    Clin Cancer Res; 2005 Jan; 11(1):129-38. PubMed ID: 15671537
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer dormancy: lessons from a B cell lymphoma and adenocarcinoma of the prostate.
    Rabinovsky R; Uhr JW; Vitetta ES; Yefenof E
    Adv Cancer Res; 2007; 97():189-202. PubMed ID: 17419946
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.